Morphine

Morphine is detected by standard opiate immunoassay screens, which are included in most drug panels from 5-panel upward. The standard cutoff is 2000 ng/mL (some panels use 300 ng/mL). Morphine is detectable in urine for approximately 2-4 days after use. Note that codeine is metabolized to morphine, so codeine use can produce positive morphine results.

In blood, morphine is detectable for approximately 12-24 hours. Saliva testing detects morphine for 1-3 days. Hair follicle testing can detect morphine for up to 90 days. Confirmatory testing via GC-MS or LC-MS/MS can distinguish morphine from other opiates.

For reagent testing: Marquis produces a purple to violet reaction (characteristic of opiates). Mecke produces dark green-blue. Mandelin produces a gray reaction. These confirm the presence of an opiate but cannot distinguish morphine from other opiates without laboratory analysis.

If prescribed morphine, follow dosing instructions precisely. Do not crush or chew extended-release formulations. Do not combine morphine with alcohol, benzodiazepines, other opioids, gabapentinoids, or other CNS depressants. Keep naloxone readily available and ensure household members know how to use it.

If using morphine from non-medical sources, be aware that any substance sold as morphine or any opioid may contain fentanyl. Use fentanyl test strips. Never use alone; have someone present who can administer naloxone if needed. Start with a small test dose, especially if tolerance is uncertain (after any period of abstinence, tolerance drops rapidly).

Morphine produces tolerance and physical dependence with regular use. Do not stop abruptly after extended use; taper under medical supervision. For individuals with opioid use disorder, evidence-based medication-assisted treatment (buprenorphine, methadone, naltrexone) significantly reduces mortality risk and improves outcomes. Never inject oral formulations, as they contain fillers and binders that can cause vascular damage, infection, and death.

Like most opioids, unadulterated morphine does not cause many long-term complications other than dependence and constipation. Outside of the extremely powerful addiction and physical dependence, the harmful or toxic aspects of morphine usage are exclusively associated with not taking appropriate precautions in regards to its administration, overdosing and using impure products.

Heavy dosages of morphine can result in respiratory depression, leading onto fatal or dangerous levels of anoxia (oxygen deprivation). This occurs because the breathing reflex is suppressed by agonism of µ-opioid receptors proportional to the dosage consumed.

Morphine can also cause nausea and vomiting; a significant number of deaths attributed to opioid overdose are caused by aspiration of vomit by an unconscious victim. This is when an unconscious or semi-conscious user who is lying on their back vomits into their mouth and unknowingly suffocates. It can be prevented by ensuring that one is lying on their side with their head tilted downwards so that the airways cannot be blocked in the event of vomiting while unconscious (also known as the recovery position).

It is strongly recommended that one use harm reduction practices when using this substance.

Dependence and abuse potential

As with other opiate-based painkillers, the chronic use of morphine can be considered extremely addictive and is capable of causing both physical and psychological dependence. When physical dependence has developed, withdrawal symptoms may occur if a person suddenly stops their usage.

Tolerance to many of the effects of morphine develops with prolonged use, including therapeutic effects. This results in users having to administer increasingly large doses to achieve the same effects. The rate at which this occurs develops at different rates for different effects with tolerance to the constipation-inducing effects developing particularly slowly. Morphine presents cross-tolerance with all other opioids, meaning that after the consumption of morphine all opioids will have a reduced effect.

The risk of fatal opioid overdoses rise sharply after a period of cessation and relapse, largely because of reduced tolerance. To account for this lack of tolerance, it is safer to only dose a fraction of one's usual dosage if relapsing. It has also been found that the environment one is in can play a role in opioid tolerance. In one scientific study, rats with the same history of heroin administration were significantly more likely to die after receiving their dose in an environment not associated with the drug in contrast to a familiar environment.

Dangerous interactions

Morphine is dangerous to use in combination with other depressants as many fatalities reported as overdoses are caused by interactions with other depressant drugs like alcohol or benzodiazepines, resulting in dangerously high levels of respiratory depression.

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

• Alcohol - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. Place affected patients in the recovery position to prevent vomit aspiration from excess. Memory blackouts are likely

• Stimulants - Stimulants increase respiration rate which allows for a higher dose of opiates than would otherwise be used. If the stimulant wears off first then the opiate may overcome the user and cause respiratory arrest.

• Benzodiazepines - Central nervous system and/or respiratory-depressant effects may be additively or synergistically present. The two substances potentiate each other strongly and unpredictably, very rapidly leading to unconsciousness. While unconscious, vomit aspiration is a risk if not placed in the recovery position blackouts/memory loss likely.

• DXM - Generally considered to be toxic. CNS depression, difficulty breathing, heart issues, and liver toxicity have been observed. Additionally if one takes DXM, their tolerance of opiates goes down slightly, thus causing additional synergistic effects.

• GHB/GBL - The two substances potentiate each other strongly and unpredictably, very rapidly leading to unconsciousness. While unconscious, vomit aspiration is a risk if not placed in the recovery position

• Ketamine - Both substances bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.

• MAOIs - Coadministration of monoamine oxidase inhibitors (MAOIs) with certain opioids has been associated with rare reports of severe adverse reactions. There appear to be two types of interaction, an excitatory and a depressive one. Symptoms of the excitatory reaction may include agitation, headache, diaphoresis, hyperpyrexia, flushing, shivering, myoclonus, rigidity, tremor, diarrhea, hypertension, tachycardia, seizures, and coma. Death has occurred in some cases.

• MXE - MXE can potentiate the effects of opioids but also increases the risk of respiratory depression and organ toxicity.

• Nitrous - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. While unconscious, vomit aspiration is a risk if not placed in the recovery position. Memory blackouts are common.

• PCP - PCP may reduce opioid tolerance, increasing the risk of overdose.

• Tramadol - Increased risk of seizures. Tramadol itself is known to induce seizures and it may have additive effects on seizure threshold with other opioids. Central nervous system- and/or respiratory-depressant effects may be additively or synergistically present.

• Grapefruit - While grapefruit is not psychoactive, it may affect the metabolism of certain opioids. Tramadol, oxycodone, and fentanyl are all primarily metabolized by the enzyme CYP3A4, which is potently inhibited by grapefruit juice. This may cause the drug to take longer to clear from the body. it may increase toxicity with repeated doses. Methadone may also be affected. Codeine and hydrocodone are metabolized by CYP2D6. People who are on medicines that inhibit CYP2D6, or that lack the enzyme due to a genetic mutation will not respond to codeine as it can not be metabolized into its active product: morphine.

Morphine occupies a unique position in international drug law: it is simultaneously one of the most tightly controlled substances and one of the most essential medicines in the world.

• United Nations: Schedule I of the Single Convention on Narcotic Drugs (1961). Morphine is also listed on the WHO Model List of Essential Medicines, creating an inherent tension between strict international controls and the recognized medical necessity for pain relief.
• United States: Schedule II under the Controlled Substances Act. Widely used in hospital, palliative, and hospice settings. Morphine manufacturing is subject to annual DEA production quotas.
• United Kingdom: Class A under the Misuse of Drugs Act 1971, Schedule 2 under the Misuse of Drugs Regulations. Available on prescription for severe and chronic pain management.
• Germany: Anlage III of the Betaubungsmittelgesetz (BtMG). Requires a special narcotic prescription for dispensing.
• Australia: Schedule 8 (controlled drug) under the Poisons Standard. Prescribing requires appropriate authority and is subject to state-level monitoring programs.
• Canada: Schedule I under the Controlled Drugs and Substances Act. Available by prescription for pain management under strict regulatory oversight.
• Japan: Classified as a narcotic under the Narcotic and Psychotropic Drugs Control Act. Medical use is permitted under tightly regulated conditions.

Despite its status as an essential medicine, global access to morphine remains profoundly unequal. The International Narcotics Control Board (INCB) has repeatedly documented that over 80% of the world's population, concentrated in low- and middle-income countries, has inadequate access to opioid pain relief. Regulatory fear of diversion, insufficient training of healthcare workers, and bureaucratic procurement barriers all contribute to what the Lancet Commission on Palliative Care has called a "global crisis of untreated pain."